Show simple item record

dc.contributor.authorKitchener, HCen_US
dc.contributor.authorAlmonte, Men_US
dc.contributor.authorWheeler, Pen_US
dc.contributor.authorDesai, Men_US
dc.contributor.authorGilham, Cen_US
dc.contributor.authorBailey, Aen_US
dc.contributor.authorSargent, Aen_US
dc.contributor.authorPeto, Jen_US
dc.contributor.authorGrp, ATSen_US
dc.date.accessioned2018-09-03T13:05:45Z
dc.date.issued2006-07-03en_US
dc.identifier1en_US
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2006, 95 pp. 56 - 61en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2514
dc.identifier.doi10.1038/sj.bjc.6603210en_US
dc.description.abstractTo evaluate the effectiveness of human papillomavirus (HPV) testing in primary cervical screening. This was a cross-sectional study from the recruitment phase of a prospective randomised trial. Women were screened for HPV in addition to routine cervical cytology testing. Greater Manchester, attendees at routine NHS Cervical Screening Programme. In all, 24 510 women aged 20 - 64 screened with liquid-based cytology (LBC) and HPV testing at entry. HPV testing in primary cervical screening. Type-specific HPV prevalence rates are presented in relation to age as well as cytological and histological findings at entry. In all, 24 510 women had adequate cytology and HPV results. Cytology results at entry were: 87% normal, 11% borderline or mild, 1.1% moderate and 0.6% severe dyskaryosis or worse. Prevalence of HPV decreased sharply with age, from 40% at age 20 - 24 to 12% at 35 - 39 and 7% or less above age 50. It increased with cytological grade, from 10% of normal cytology and 31% of borderline to 70% mild, 86% moderate, and 96% of severe dyskaryosis or worse. HPV 16 or HPV 18 accounted for 64% of infections in women with severe or worse cytology, and one or both were found in 61% of women with severe dyskaryosis but in only 2.2% of those with normal cytology. The majority of young women in Greater Manchester have been infected with a high-risk HPV by the age of 30. HPV testing is practicable as a primary routine screening test, but in women aged under 30 years, this would lead to a substantial increase in retesting and referral rates. HPV 16 and HPV 18 are more predictive of underlying disease, but other HPV types account for 30% of high-grade disease.en_US
dc.format.extent56 - 61en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherNATURE PUBLISHING GROUPen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleHPV testing in routine cervical screening: cross sectional data from the ARTISTIC trialen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/sj.bjc.6603210en_US
rioxxterms.licenseref.startdate2006-07-03en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBRITISH JOURNAL OF CANCERen_US
pubs.notesaffiliation: Kitchener, HC (Reprint Author), Univ Manchester, Div Human Dev, Hathersage Rd, Manchester M13 0JH, Lancs, England. Univ Manchester, Div Human Dev, Manchester M13 0JH, Lancs, England. Univ London London Sch Hyg & Trop Med, Non Communicable Dis Epidemiol Unit, London WC1E 7HT, England. Univ Manchester, Div Human Dev, Manchester M13 0JH, Lancs, England. Cent Manchester & Manchester Childrens Univ Hosp, Dept Cytol, Manchester M13 9WL, Lancs, England. Inst Canc Res, Canc Res UK Epidemiol & Genet Unit, Sutton SM2 5NG, Surrey, England. Cent Manchester & Manchester Childrens Univ Hosp, Dept Virol, Manchester M13 9WL, Lancs, England. Univ Manchester, Div Human Dev, Manchester M13 0JH, Lancs, England. Univ London London Sch Hyg & Trop Med, Non Communicable Dis Epidemiol Unit, London WC1E 7HT, England. Inst Canc Res, Canc Res UK Epidemiol & Genet Unit, Sutton SM2 5NG, Surrey, England. keywords: cervical screening; HPV detection; typing; cytology keywords-plus: HUMAN-PAPILLOMAVIRUS; CANCER; WORLDWIDE; WOMEN research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] researcherid-numbers: Almonte, Maribel/O-3286-2016 number-of-cited-references: 10 times-cited: 144 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: Br. J. Cancer doc-delivery-number: 057TK unique-id: ISI:000238617900009 oa: gold_or_bronze da: 2018-09-03en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume95en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorGilham, Cen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/